Taysha Gene Therapies
TSHA
54 hedge funds and large institutions have $27M invested in Taysha Gene Therapies in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 22 reducing their positions, and 8 closing their positions.
2.35% less ownership
Funds ownership: 36.26% → 33.9% (-2.4%)
8% less funds holding
Funds holding: 59 → 54 (-5)
50% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 22
51% less capital invested
Capital invested by funds: $54.7M → $27M (-$27.7M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QPW
Quantum Private Wealth
Tampa,
Florida
|
+$259K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$251K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$180K |
| 4 |
CC
Carlson Capital
Dallas,
Texas
|
+$127K |
| 5 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
+$53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$852K |
| 2 |
Renaissance Technologies
New York
|
-$382K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$341K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$320K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$271K |
TSHA Hedge Fund Activity: Q3 2022 in Review
54 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q3 2022, worth a combined $27M — down 51% from $54.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TSHA and 3 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 11 added.
The largest buyer was Quantum Private Wealth, adding an estimated $259K. The largest seller was JP Morgan Chase, cutting an estimated $852K.
- 54 institutional investors held Taysha Gene Therapies (TSHA) as of Q3 2022, down from 59 in Q2 2022.
- Funds reported $27M of Taysha Gene Therapies stock for Q3 2022, down 51% quarter-over-quarter.
- 3 funds opened new Taysha Gene Therapies positions in Q3 2022 and 8 closed out, a net change of -5 holders.
- The largest Taysha Gene Therapies buyer in Q3 2022 was Quantum Private Wealth, an estimated $259K added.
- The largest Taysha Gene Therapies seller in Q3 2022 was JP Morgan Chase, an estimated $852K sold.
Based on aggregated 13F filings for Q3 2022.